PedAM
Pediatric Disease Annotations & Medicines
| Disease | pleural effusion disorder |
| Phenotype | |lung cancer |
| Sentences | 66 |
| PubMedID- 26134225 | Introduction: a subset of non-small-cell lung cancer (nsclc) patients with malignant pleural effusion and/or malignant pleural nodules is now classified as stage iv and is generally considered a contraindication to surgery. |
| PubMedID- 24748865 | The cytological positivity of pleural effusion in lung cancer in the literature is 3.7–38.6% [13]. |
| PubMedID- 23681012 | In pleural effusion from patients with lung cancer, the level of mir-198 was also decreased. |
| PubMedID- 23925664 | Vascular endothelial growth factor (vegf) is involved in non-small cell lung cancer (nsclc) with malignant pleural effusion (mpe), but little is known regarding the efficacy of bevacizumab (bev) with carboplatin-paclitaxel (cp) for nsclc with mpe. |
| PubMedID- 21108775 | She had lung cancer with pleural effusion. |
| PubMedID- 23649436 | Thoracoscopic biopsy of the pleura has the highest diagnostic yield for diagnosis of metastatic pleural effusion in a patient with lung cancer. |
| PubMedID- 23408789 | Their study showed that there were increased numbers of regulatory cd4+cd25+ t cells in malignant pleural effusion from patients with lung cancer compared with pleural lavage from patients with lung cancer without pleural effusion, and that these cells had constitutive high-level expression of foxp3 and cytotoxic lymphocyte-associated antigen-4. |
| PubMedID- 22305792 | Evaluation of serum and pleural levels of endostatin and vascular epithelial growth factor in lung cancer patients with pleural effusion. |
| PubMedID- 22744209 | After testing a protocol for ad.cd transfer and lung tumor burden control in a lewis mouse model, we used this technique in the management of lung cancer patients with malignant pleural effusion (mpe): two cases are presented investigating the possible enhancement of anticancer effect in both non-small-cell lung cancer (nsclc) and small-cell lung cancer (sclc) by local activation of the pro-drug 5-fc. |
| PubMedID- 24913066 | Introduction/background: non-small-cell lung cancer patients with malignant pleural effusion have a poor overall median survival (4.3 months). |
| PubMedID- 25999646 | Patients in this study are enrolled in a phase i clinical trial of hpph-mediated pdt for the treatment of non-small cell lung cancer with pleural effusion. |
| PubMedID- 25800577 | It has the characteristics of inhibiting trypsin and high expression in the serum or malignant pleural effusion of patients with lung cancer. |
| PubMedID- 24851110 | lung cancer patients suspected of having a pleural effusion undergo a chest x-ray and contrast-enhanced computed tomography to confirm the presence of fluid in the pleural cavity and to evaluate the pleura for nodularity or thickening, which may suggest metastasis [4]. |
| PubMedID- 21625182 | Materials and methods: we analyzed f-18 fdg pet/ct images of 33 lung cancer patients with pleural effusion. |
| PubMedID- 20819493 | Objective: to compare the therapeutic effects of pleural perfusion of ndp and cddp in non-small cell lung cancer (nsclc) patients with malignant pleural effusion, their quality of life and toxic side effects. |
| PubMedID- 22363829 | In contrast, the pulmonary edema developed on day 16 in patients 4 who had an underlying lung cancer with malignant pleural effusion obviously resulted from fluid overload. |
Page: 1 2